Work

A phase I/IIa, open-label, multicenter, non-randomized clinical trial to assess the safety and efficacy of CYNK-001 in combination with recombinant human interleukin 2 in adults with recurrent resection eligible IDH1 wild-type glioblastoma (GBM).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps2080

Authors: Daniela Annenelie Bota, Behnam Badie, Amy B. Heimberger, Nazanin Majd, Mark S. Awadalla, John Colerangle, Shawn He, Sharmila Koppisetti, William van der Touw, Robert Hariri, Andrew L Pecora

Institutions: University of California, Irvine, City Of Hope National Medical Center, The University of Texas MD Anderson Cancer Center, Celularity (United States), Hackensack University Medical Center

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286296467

Cites:

Cited by: 2

Related to: 10